Patent intelligence · US
US 10806763
Compositions of polymeric myrcene
Compositions of polymeric myrcene
Patent details — US 10806763
- Jurisdiction
- US
- Status
- granted
- Grant date
- Oct 20, 2020
- Expiration
- Oct 15, 2040
- Applicant
- REGENERA PHARMA LTD.
- Claims
- 12
- CPC classes
- A61K, A61K36/22, A61P, A61P1/00
Quick answer
US 10806763 (Compositions of polymeric myrcene) is held by REGENERA PHARMA LTD.. Status: granted. Granted Oct 20, 2020. Expires Oct 15, 2040 (14 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- REGENERA PHARMA LTD.
- Grant date
- Expiration
- Claims
- 12
- CPC classes
- A61K, A61K36/22, A61P, A61P1/00, A61P11/00, A61P17/00
More from REGENERA PHARMA LTD.
Related pharmaceutical patents in our USPTO index.
-
US 12428463
Chimeric antigen receptors targeting abnormal glycobiology
granted -
US 12427148
Cancer treatment targeted to tumor adaptive responses to protein synthesis stress
granted -
US 12428416
ERK inhibitors and uses thereof
granted -
US 12427151
Compositions and method of treating cancer
granted -
US 12427197
Methods of producing cobalt nanoparticles and hollow metal nanospheres
granted -
US 12428489
Human PD-L2 antibodies and methods of use therefor
granted -
US 12427155
Treatment for tau-related diseases
granted -
US 12428455
Dominant negative CEBPB and CEBPD proteins and methods of use for decreasing viability of neoplastic cells
granted
Frequently asked questions
What is US patent 10806763?
US 10806763 (Compositions of polymeric myrcene) is held by REGENERA PHARMA LTD.. Status: granted. Granted Oct 20, 2020. Expires Oct 15, 2040 (14 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 10806763?
REGENERA PHARMA LTD. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 8,292 pharmaceutical patents for this assignee.
When does US 10806763 expire?
Our index shows an expiration date of Oct 15, 2040 (14 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.